DBV Technologies stock price soars due to new trial data for peanut patch

Investing.com – DBV Technologies (Euronext:DBV - Nasdaq: DBVT) stock rose 7.9% on Monday after the company announced additional data from its Phase 3 VITESSE clinical trial at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting.

Data showed that at 12 months, approximately 83% of children treated with the VIASKIN peanut patch increased their eliciting dose, compared to about 48% in the placebo group. Additionally, around 60% of treated children increased their eliciting dose by at least two dose levels, compared to 23% in the placebo group.

The company stated that the VITESSE study is the largest food allergy immunotherapy trial to date, evaluating the effectiveness of the VIASKIN peanut patch in treating children aged 4 to 7 with peanut allergies. The study met its primary endpoint: at 12 months, 46.6% of children in the VIASKIN peanut patch group responded to treatment, compared to 14.8% in the placebo group.

Data also showed that between baseline and 12 months, 24% of children in the placebo group experienced a decrease in eliciting dose, while only 6.4% of children in the patch treatment group did.

Among children with a baseline eliciting dose of 30 mg or less, 49.3% were responders, compared to 14.7% in the placebo group. For children with a baseline eliciting dose of 100 mg, 43.1% were responders, compared to 14.6% in the placebo group.

The treatment was well tolerated, with most adverse events during treatment being mild local reactions at the application site, consistent with previous Phase 3 study results.

DBV Technologies plans to submit a Biologics License Application (BLA) to the FDA in the first half of this year.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.